Investigating the Effect of Vortioxetine in Adult ADHD Patients
Public ClinicalTrials.gov record NCT02327013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
Study identification
- NCT ID
- NCT02327013
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Interventions
- vortioxetine 10 mg tablet Drug
- vortioxetine 20 mg tablet Drug
- Placebo tablet Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Aug 31, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Mar 6, 2018
2014 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US015 | Beverly Hills | California | — | — |
| US002 | Garden Grove | California | — | — |
| US004 | National City | California | — | — |
| US013 | Bradenton | Florida | — | — |
| US006 | Gainesville | Florida | — | — |
| US010 | Alpharetta | Georgia | — | — |
| US014 | Libertyville | Illinois | — | — |
| US011 | Baltimore | Maryland | — | — |
| US009 | Boston | Massachusetts | — | — |
| US016 | Las Vegas | Nevada | — | — |
| US005 | New York | New York | — | — |
| US008 | New York | New York | — | — |
| US001 | Austin | Texas | — | — |
| US007 | Herndon | Virginia | — | — |
| US003 | Bellevue | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02327013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02327013 live on ClinicalTrials.gov.